Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs American Homes 4 Rent Class A (AMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs American Homes 4 Rent Class A — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while American Homes 4 Rent Class A trades at $34.07 (market cap $12.28B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.4× American Homes 4 Rent Class A's market cap, and American Homes 4 Rent Class A pays a 3.87% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | AMH | |
|---|---|---|
Market Cap | $29.60B | $12.28B |
Sector | Health | Real Estate |
52-Week High | $491.22 | $35.82 |
52-Week Low | $205.48 | $27.38 |
Enterprise Value | $27.56B | $17.35B |
Dividend Yield | — | 3.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
AMH (American Homes 4 Rent) trades at $33.87, down 0.76% today, with a bullish technical signal and strong fundamentals. The stock exhibits consistent earnings beats, with Q2 2026 FFO of $0.49 per share exceeding estimates (Zacks Investment Research, July 30, 2026). Revenue growth trends upward, reaching $1.85 billion in 2025, while net income margin improved to 25.53% in 2026. Recent news highlights institutional interest and raised 2026 guidance, supporting positive sentiment.
The outlook for AMH remains favorable due to robust operational performance and analyst consensus, but risks include regulatory changes affecting institutional home buying and high debt levels. With a $36.45 average price target and no sell ratings, Wall Street leans bullish, though investors should monitor housing policy impacts and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →
